The New Default. Your hub for building smart, fast, and sustainable AI software

See now
Abstract, minimalist image for an article about femtech.

FemTech: another buzzword or a rising digital innovation in female healthcare?

Piotr Zając
|   Updated Nov 8, 2026

FemTech is not a buzzword. It's a market of technology products built around women's health, valued at an estimated $45.6 billion in 2025 and projected to reach $145.5 billion by 2033. Prescription birth control apps, wearable fertility trackers, Bluetooth-connected breast pumps and pelvic floor trainers have all gone mainstream since Ida Tin coined the term "femtech" in 2016. The more useful question for anyone building in this space is which FemTech products last. Below: why the market exists, what Elvie and Clue teach, and what it takes to build a FemTech product women will trust.

Executive Summary

FemTech, technology designed around women's health needs, is a real and growing market rather than a passing label: women spend 25% more of their lives in poor health than men, and closing that gap could add at least $1 trillion a year to the global economy by 2040. Investment is moving toward clinically validated products, with women's health companies raising a record $1.55 billion in disclosed equity in 2025. Demand alone doesn't guarantee survival, though: Elvie raised over $186 million and still ended up in administration. The FemTech products that last treat health-data privacy, regulatory status and clinical evidence as core product decisions from day one.

What Is FemTech?

FemTech (female technology) is the umbrella term for software, diagnostics, devices and services that use technology to address women's health needs. Ida Tin, co-founder of the Berlin-based period and ovulation tracker Clue, coined it to legitimize the female health technology market and draw investment and innovation into it.

Female health, sexuality, fertility and reproduction were the first focus areas, but the category now covers a woman's whole life course:

FemTech segment

What the products do

Examples

Menstrual and cycle health

Track cycles, predict ovulation, flag irregularities

Clue

Fertility and contraception

Monitor fertility, prevent pregnancy without hormones

Natural Cycles

Pregnancy and postpartum

Wearable breast pumps, doula, lactation and recovery care

Willow, Partum Health

Pelvic and sexual health

Pelvic floor training with biofeedback

Elvie Trainer

Menopause and midlife

Virtual menopause and midlife care

Midi Health

Maternal mental health

Postpartum depression screening and therapy access

Maven, Dionysus Health

Why Is FemTech a Separate Market, Not a Niche?

FemTech exists as its own category because, for decades, healthcare products were designed, developed and delivered without paying attention to physiological differences between men and women. Women make up 49.7% of the world's population, so a market that serves them is hardly a niche. Yet a McKinsey Health Institute and World Economic Forum report found that women spend 25% more of their lives in poor health than men, and estimated that closing the gap could add at least $1 trillion to global GDP annually by 2040.

That gap starts in product design. A solution that works for a man won't necessarily work the same way for a woman, and products built on male-default data can miss symptoms or ignore female-specific conditions altogether. Companies that specialize in women's health can go deep where general healthcare products stay shallow, and that focus is where the commercial opportunity sits.

Investors have noticed, but they've become choosier. According to W Group's global women's health investment report, women's health companies raised a record $1.55 billion in disclosed equity in 2025, up 41% on 2024, and the money favored clinically focused companies over lifestyle or consumer-only products. The same report shows where founders get stuck: of the up to 40 companies that raise pre-seed or seed rounds each year, only about 20 to 25 reach Series A.

On HealthTech Pulse, Rachel Braun Scherl, Managing Partner of SPARK Solutions for Growth, named the pitch mistake she sees most often in women’s health:

The biggest mistake I see founders making is presenting a story other than the economic case.

FemTech Is Not Niche: Funding Gap US vs Europe ft. Rachel Braun Scherl

Investors weigh a FemTech deal against AI and other tech deals in the same fund, so the pitch has to show uptake, what buyers use today and the potential return.

What Can FemTech Founders Learn From Elvie and Clue?

Two of Europe's best-known FemTech companies show both sides of the market: strong demand, and how expensive it can be to serve it.

Elvie: strong products, heavy costs

Elvie was one of the most prominent FemTech companies in the UK. Founded by Tania Boler in 2013, it raised over $186 million from investors including Octopus Ventures and BlackRock. Its award-winning products, a pelvic floor trainer and a wearable breast pump, addressed real problems: childbirth and the normal wear and tear of living put stress on a woman's pelvic floor, which can lead to incontinence and, in severe cases, uterine prolapse.

Monterail built the companion app for the Elvie Trainer, an FDA-registered pelvic floor device. We audited and rebuilt Elvie's existing prototype as native iOS and Android apps that give real-time biofeedback over Bluetooth Low Energy, improving device connectivity and data security along the way. The app has passed 100,000 downloads and holds a 4.6 rating on the App Store. We also built the native apps for the Elvie Pump, Elvie's wireless breast pump, including a system that generates validation documentation for FDA and MDR submission reviews.

Demand was never Elvie's problem. Its revenue grew from £37 million in 2020 to £78 million in 2022, but losses widened from £22 million in 2021 to £29 million in 2022. In March 2025, the company entered administration and was acquired by its US competitor Willow. Hardware-led FemTech carries manufacturing, inventory and retail distribution on top of software, and those costs can outrun even strong sales.

Clue: from period tracker to regulated product

Clue, the Berlin-based app that gave the category its name, took a software-first path. Founded in 2012, it now reaches more than 100 million women and people with cycles, and in January 2026 it secured a strategic investment from growth equity firm Verdane, the largest in its history (the terms weren't disclosed).

Clue's most instructive move was crossing into regulated territory. In 2021, its birth control feature received FDA clearance as a digital contraceptive, following Natural Cycles, which in 2018 became the first app the FDA cleared as a method of birth control. That step turns a wellness app into a medical device, with the clinical evidence, quality management and post-market obligations that come with it.

Where Is FemTech Innovation Heading in 2026?

The clearest shift is from tracking to care. Early FemTech apps recorded what users told them. The products attracting attention now combine that data with clinical services, diagnostics and validated screening.

Maternal mental health shows the shift best. Depression (including postpartum depression) and anxiety were long a gap in women's health, and FemTech World's 2026 trends roundup names maternal mental health as an area taking center stage, with digital platforms building in emotional check-ins, validated screening tools and access to therapists. Maven, whose women's and family health platform includes support for postpartum depression and anxiety, raised a $125 million Series F in October 2024 at a reported $1.7 billion valuation. Dionysus Health goes further, from screening to prediction: its myLuma blood test estimates a pregnant woman's risk of postpartum depression and was due in some doctors' offices in California, Texas and Florida from January 2026, though it isn't FDA-approved yet.

The same roundup flags menopause, sexual health and non-hormonal contraception as underfunded compared with fertility. For founders, that's where the open space is.

What Does It Take to Build a FemTech Product?

Building in FemTech means handling some of the most sensitive data a person can share, often under medical regulation. Four decisions shape the product early, and each is expensive to fix later.

Privacy comes first. Cycle, fertility and sexual health data is highly sensitive, and in the US a consumer app usually falls outside HIPAA. The FTC has filled part of that gap: it ordered Flo Health in 2021 to get users' affirmative consent before sharing health data, after alleging the period tracker shared it with Facebook and Google, and in 2024 it updated the Health Breach Notification Rule to cover health apps, including unauthorized disclosures. In the EU and UK, health data is special-category data under GDPR. A 2025 University of Cambridge report warned that menstrual data can be used to restrict abortion access and called for granular consent and full data deletion. Third-party analytics SDKs, data minimization and data residency are product decisions with direct consequences for user trust.

Regulatory status is the second decision. Once an app claims to prevent pregnancy, diagnose a condition or guide treatment, it's likely to be regulated as a medical device, by the FDA in the US or under the Medical Device Regulation (MDR) in the EU. Natural Cycles and Clue show it's achievable, but it means clinical evidence, a quality management system and a longer route to market. Many teams launch a wellness product and add regulated features later. That works only if the architecture, documentation and data handling were built with the move in mind.

Clinical credibility is the third. Investors increasingly back clinically focused companies, so involving clinicians in product design and planning how you'll validate outcomes is cheaper at the start than retrofitted before a funding round.

The business model is the fourth, and Elvie's story is the warning. Connected hardware adds manufacturing, inventory and retail costs to everything a software product needs. If software alone can solve the problem, or you can partner with an existing device maker, consider that before building your own device.

Key Takeaways

  • FemTech was a $45.6 billion market in 2025, projected to reach $145.5 billion by 2033.

  • Women spend 25% more of their lives in poor health than men, and that gap is the market.

  • Investors now favor clinically focused women's health companies over consumer-only products.

  • Demand doesn't guarantee survival: Elvie raised over $186 million and still went into administration.

  • Privacy, regulatory status and clinical evidence are product decisions, not paperwork for later.

So, Is FemTech a Buzzword?

No. FemTech is the next step for better women's healthcare: a market built on a measurable health gap, backed by growing investment, with products that already help millions of women. What separates lasting FemTech companies from the rest is execution: privacy built in from day one, a clear answer on whether the product is a medical device, clinical evidence, and a business model that can carry its costs.

If you're planning a women's health product, Monterail can help you decide what's worth building and then build it, from product discovery and design to secure web and mobile apps. Get in touch to talk through your idea.

FemTech FAQ

Author photo for Piotr Zajac
Piotr Zając
HealthTech Director
Linkedin
Piotr, Monterail’s Director of HealthTech brings over 15 years of entrepreneurial leadership and strategic innovation to the MedTech and HealthTech sectors. Piotr has demonstrated exceptional ability to build and scale healthcare solutions. Former President of EO Poland, part of the world's largest entrepreneur network. Combining his entrepreneurial background with Management 3.0 principles, Piotr specializes in helping organizations drive sustainable innovation in the rapidly evolving HealthTech landscape.